SCHEMBL4983397

SCHEMBL4983397

O=C(Cc1c[nH]cn1)N1CCC(c2cc[c]c(C3=CCCCC3)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 17/20 0.43
CYP3A4 P08684 8/20 0.43
CYP2C19 P33261 6/20 0.41
CYP2C9 P11712 1/20 0.41
KIT P10721 8/20 0.40
BMPR1B O00238 2/20 0.39
PLK4 O00444 2/20 0.39
STK25 O00506 2/20 0.39
RIOK3 O14730 2/20 0.39
CHEK1 O14757 2/20 0.39
GAK O14976 2/20 0.39
DCLK1 O15075 2/20 0.39
MUSK O15146 2/20 0.39
EPHB6 O15197 2/20 0.39
PDPK1 O15530 2/20 0.39
MAP3K13 O43283 2/20 0.39
DAPK3 O43293 2/20 0.39
MAP3K7 O43318 2/20 0.39
NUAK1 O60285 2/20 0.39
JAK2 O60674 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977257 0.85 CSF1R (0.56) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL18240980 0.79 CSF1R (0.41) CSF1RCYP3A4CYP2C19CYP2C9KIT
Trifluoroacetic Acid SCHEMBL2944468 0.78 CSF1R (0.47) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL2944467 0.77 CSF1R (0.56) CSF1RCYP3A4CYP2C19CYP2C9KIT
Trifluoroacetic Acid SCHEMBL2944465 0.77 CSF1R (0.45) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL18240960 0.74 CSF1R (0.45) CSF1RCYP3A4CYP2C19KITNTRK1
SCHEMBL4057863 0.73 CSF1R (0.49) CSF1RCYP3A4CYP2C19KITNTRK1
SCHEMBL13105560 0.72 CSF1R (0.64) CSF1RCYP3A4CYP2C19CYP2C9KIT
SCHEMBL18240996 0.72 CSF1R (0.54) CSF1RCYP3A4CYP2C19CYP2C9RIPK1
SCHEMBL13179233 0.72 CSF1R (0.59) CSF1RCYP3A4CYP2C19CYP2C9KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 US disclosed
EP-2397138-B1 Aromatic amide derivatives as C-KIT kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-12-11 EP disclosed
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 CSF1R 2973/4885CYP3A4 4130/4885CYP2C19 4271/4885
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 CSF1R 2973/4885CYP3A4 4130/4885CYP2C19 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.